GSK's MRNA Flu Vaccine Candidate Advances To Phase III Trial

GSK will move its investigational mRNA seasonal flu vaccine candidate into Phase III testing after Phase II data showed stronger immune responses versus standard and high-dose flu vaccines in both younger and older adults. The advancement suggests improved immunogenicity across age groups and de-risks the program for later-stage development. The news is likely incremental for near-term markets but positive for the company’s biotech pipeline outlook.